

Press release

Zug, 8 October 2009

Paratek Pharmaceuticals, a portfolio company of HBM BioVentures, signs licence agreement over USD 485 million

Paratek Pharmaceuticals announced today that it has entered into a licence agreement with Novartis. Under the agreement, Novartis acquires the exclusive right to market the broad-spectrum antibiotic PTK 0796 worldwide, in return for which Paratek will receive up to USD 485 million in the form of an up-front payment and future milestone payments. Paratek will also receive a royalty on net sales of PTK 0796 around the world.

The broad-spectrum antibiotic PTK 0796, which can be administered once daily as an infusion or orally to treat various kinds of life-threatening infections, is in Phase 3 clinical trials. The cooperation agreement gives Paratek Pharmaceuticals an experienced partner for the continued development and marketing of PTK 0796. The two companies will share responsibility and costs for the further development of the product candidate.

HBM BioVentures has invested USD 6 million in Paratek Pharmaceuticals, a private company based in Boston (USA), over three financing rounds since 2001. In strict compliance with EVCA and IFRS valuation principles, the value of this investment in the books of HBM BioVentures will not be increased in spite of this positive news.

Dr. Andreas Wicki, CEO of HBM BioVentures, comments: "This cooperation agreement between Novartis and Paratek Pharmaceuticals is another example validating the innovation quality and the intrinsic value embedded in the portfolio of HBM BioVentures".

To find out more, please visit the Paratek Pharmaceuticals website at www.paratekpharm.com.

For further information, please contact Dr. Andreas Wicki, CEO of HBM BioVentures Ltd, tel.: +41 41 768 11 08, andreas.wicki@hbmbioventures.com.

HBM BioVentures Ltd

As a venture capital company, HBM BioVentures is invested globally in some 35 mature emerging companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The primary products of many of HBM BioVentures'

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA



portfolio companies are either at an advanced stage of development or already available on the market. The company focuses on unlisted emerging companies. Two thirds of investment capital is invested in private companies with high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on the SIX Swiss Exchange (ticker: HBMN). Visit www.hmbioventures.com.

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM BioVentures Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

HBM BioVentures Ltd
Bundesplatz 1
CH-6300 Zug / Switzerland
Tel:+41 41 768 11 08
Fax:+41 41 768 11 09
info@hmbioventures.com
www.hmbioventures.com